Equities analysts expect Charles River Laboratories (NYSE:CRL) to post earnings of $1.47 per share for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Charles River Laboratories’ earnings, with the lowest EPS estimate coming in at $1.45 and the highest estimate coming in at $1.52. Charles River Laboratories reported earnings of $1.29 per share during the same quarter last year, which suggests a positive year over year growth rate of 14%. The business is scheduled to report its next earnings results on Wednesday, August 8th.
On average, analysts expect that Charles River Laboratories will report full year earnings of $5.82 per share for the current financial year, with EPS estimates ranging from $5.73 to $5.90. For the next fiscal year, analysts forecast that the company will report earnings of $6.52 per share, with EPS estimates ranging from $6.41 to $6.60. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Charles River Laboratories.
Charles River Laboratories (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 10th. The medical research company reported $1.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.12. Charles River Laboratories had a net margin of 6.78% and a return on equity of 24.96%. The firm had revenue of $493.97 million during the quarter, compared to analysts’ expectations of $480.03 million. During the same quarter in the prior year, the business earned $1.29 EPS. Charles River Laboratories’s quarterly revenue was up 10.8% compared to the same quarter last year.
Several analysts have recently commented on the stock. TheStreet cut shares of Charles River Laboratories from an “a-” rating to a “c+” rating in a research note on Tuesday, February 13th. Zacks Investment Research cut shares of Charles River Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, May 15th. ValuEngine cut shares of Charles River Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 7th. JPMorgan Chase raised their target price on shares of Charles River Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. Finally, SunTrust Banks cut shares of Charles River Laboratories from a “buy” rating to a “hold” rating and raised their target price for the stock from $107.89 to $111.00 in a research note on Monday, January 22nd. They noted that the move was a valuation call. Nine investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Charles River Laboratories has an average rating of “Buy” and an average target price of $115.86.
In other news, CEO James C. Foster sold 4,800 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $106.69, for a total value of $512,112.00. Following the completion of the transaction, the chief executive officer now owns 306,914 shares in the company, valued at approximately $32,744,654.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William D. Barbo sold 2,320 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $108.08, for a total transaction of $250,745.60. Following the completion of the transaction, the insider now owns 21,276 shares of the company’s stock, valued at approximately $2,299,510.08. The disclosure for this sale can be found here. Insiders sold a total of 58,264 shares of company stock valued at $6,390,411 in the last quarter. Insiders own 2.10% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in CRL. Principal Financial Group Inc. increased its holdings in Charles River Laboratories by 2.6% during the 1st quarter. Principal Financial Group Inc. now owns 207,753 shares of the medical research company’s stock valued at $22,176,000 after acquiring an additional 5,293 shares in the last quarter. WINTON GROUP Ltd increased its holdings in Charles River Laboratories by 1.7% during the 1st quarter. WINTON GROUP Ltd now owns 57,049 shares of the medical research company’s stock valued at $6,089,000 after acquiring an additional 940 shares in the last quarter. Wesbanco Bank Inc. purchased a new position in Charles River Laboratories during the 1st quarter valued at about $1,327,000. Xact Kapitalforvaltning AB increased its holdings in Charles River Laboratories by 33.1% during the 1st quarter. Xact Kapitalforvaltning AB now owns 6,037 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in Charles River Laboratories by 2.0% during the 1st quarter. Royal Bank of Canada now owns 390,330 shares of the medical research company’s stock valued at $41,664,000 after acquiring an additional 7,767 shares in the last quarter. Institutional investors and hedge funds own 97.76% of the company’s stock.
CRL stock opened at $106.61 on Friday. Charles River Laboratories has a one year low of $89.37 and a one year high of $119.05. The firm has a market capitalization of $5.08 billion, a PE ratio of 20.23, a PEG ratio of 1.34 and a beta of 0.69. The company has a quick ratio of 1.78, a current ratio of 2.07 and a debt-to-equity ratio of 0.99.
Charles River Laboratories Company Profile
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Get a free copy of the Zacks research report on Charles River Laboratories (CRL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.